News for Heron Therapeutics, Inc. (0J4V.L)

On March 4, 2025, TANG KEVIN C (Trades, Portfolio), a recognized market expert, executed a significant stock transaction involving Aurinia Pharmaceuticals Inc (

Net Income (Q4 2024): $3.6 million.Net Revenues (Full Year 2024): $144.2 million, a 14% year-over-year increase.Adjusted EBITDA (Full Year 2024): $8.6 million.

Feb 27, 2025 / 01:00PM GMTOperator Good day and thank you for standing by and welcome to the Heron Therapeutics Q4 2024 conference call. (Operator Instructions)

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ETCompany ParticipantsMelissa Jarel - Executive Director,...

Net Income: Achieved Q4 2024 GAAP Net Income of $3.6 million, marking a significant turnaround from the previous year's loss.Quarterly Revenue: Reported Q4 202

PR NewswireCARY, N.C., Feb. 27, 2025 Achieved Q4 2024 GAAP Net Income of $3.6 millionGenerated full-year 2024 Net Revenue of $144.2 million, up 14% year-ov

PR NewswireSAN DIEGO, Dec. 23, 2024 SAN DIEGO, Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commerci

On December 10, 2024, Velan Capital Investment Management LP (Trades, Portfolio) executed a significant transaction involving Protara Therapeutics Inc (TARA). T

Israel-based PainReform Ltd. (PRFX), a clinical stage specialty pharmaceutical company is up over 142 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Heron stock surges on win in patent case against Fresenius

PR NewswireSAN DIEGO, Dec. 3, 2024 ”” Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC ””SAN DIEGO, Dec. 3, 2024 /PRNewswi

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ETCompany ParticipantsMelissa Jarel - Executive...

Net Product Sales: Achieved $32.81 million for Q3 2024, surpassing the previous year's $31.43 million, indicating a positive growth trajectory.Gross Profit: In

Overview of the Recent Transaction On September 30, 2024, Velan Capital Investment Management LP (Trades, Portfolio) executed a significant transaction by acqui

Aug 06, 2024 / 08:30PM GMTOperator Thank you for standing by. My name is Jeremaine, and I will be your conference operator today. At this time, I would like to

Worldwide increase in the incidence of cancer is driving the demand for chemotherapy induced nausea and vomiting treatment market....

As September unfolds, let us review some of the regulatory news that made headlines last month and look ahead to what this month has in store..

The NSAIDs market is experiencing significant growth due to the rising incidence of chronic pain and inflammatory conditions such as arthritis and...

Document UNITED STATES SECURITIES...